Another biologic enters phase 2 testing for SS

The clinical trial is not yet open for recruitment, and it isn’t clear from the posting where recruitment will occur. The new biologic is identified as AMG 557/MEDI5872 and produced by Amgen and AstraZeneca. The drug already completed a Phase 1 trial for SLE (lupus). From the Amgen site:

AMG 557 is a human monoclonal antibody that inhibits the action of B7 related protein (B7RP-1). It is being investigated as a treatment for systemic lupus erythematosus. AMG 557 is being jointly developed in collaboration with AstraZeneca Plc.

Considering the similarities between SLE and SS, I would expect to see more drugs being tested for both SLE and SS at the same time. With a phase 2 trial that has not yet started, it will be years before SS patients have an approved drug, but it’s always nice to widen the pipeline.

Posted in Clinical Trials, Research, Treatment Tagged with:
WordPress Appliance - Powered by TurnKey Linux